ReviewJournal of the American Heart Association2023
Circulating Biomarkers in Coronary Microvascular Dysfunction.
Review in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Genome-wide association study of coronary flow reserve assessed by cardiac perfusion PET suggests a role for NF-κB pathway.Nature cardiovascular research · 2026Article
- Association of reduced Cu,Zn-superoxide dismutase with coronary microvascular dysfunction-An observational study of oxidative stress markers.International journal of cardiology. Heart & vasculature · 2026Article
- The Potential Role of Baseline FT3/FT4 Ratio as a Prognostic Biomarker for Patients With Ischemic Non-Obstructive Coronary Artery Disease.Clinical cardiology · 2026Article
- Biomarkers of Cardiac Metabolic Flexibility in Health, HFrEF and HFpEF.International journal of molecular sciences · 2026Review
- Efficacy and safety of acupuncture for coronary microvascular disease: study protocol for a pilot randomized controlled trial.Frontiers in cardiovascular medicine · 2026Article
- Prediction of Coronary Artery Spasm in Patients Without Obstructive Coronary Artery Disease Using a Comprehensive Clinical, Laboratory and Echocardiographic Risk Score.Journal of clinical medicine · 2025Article
- Coronary microvascular disease in heart failure with preserved ejection fraction.Physiological reports · 2025Review
- Focusing on microvascular function in heart failure with preserved ejection fraction.Heart failure reviews · 2025Review
- Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.World journal of cardiology · 2025Review
- Heart failure and microvascular dysfunction: an in-depth review of mechanisms, diagnostic strategies, and innovative therapies.Annals of medicine and surgery (2012) · 2025Review
- The Role of Circulating Biomarkers in Patients with Coronary Microvascular Disease.Biomolecules · 2025Review
- Retinal Microangiopathy as a Marker of Coronary Atherosclerotic Heart Disease.International journal of general medicine · 2025Review
- From meal to malfunction: exploring molecular pathways, biomarkers and interventions in postprandial cardiometabolic health.Frontiers in cardiovascular medicine · 2025Review
- Monocyte IL-1β predicts adverse cardiovascular events and associates with coronary microvascular dysfunction in kidney transplant recipients.Frontiers in cardiovascular medicine · 2025Article
- Epicardial adipose tissue attenuation on computed tomography in women with coronary microvascular dysfunction: A pilot, hypothesis generating study.Atherosclerosis · 2024Article
- Endothelial microRNAs in INOCA patients with diabetes mellitus.Cardiovascular diabetology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary microvascular dysfunction is an underdiagnosed pathologic process that is associated with adverse clinical outcomes. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in the diagnosis and management of coronary microvascular dysfunction. We present an updated review of circulating biomarkers in coronary microvascular dysfunction representing key pathologic processes, including inflammation, endothelial dysfunction, oxidative stress, coagulation, and other mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.